Artelo Biosciences (ARTL) Corporate presentation summary

Strategic focus and pipeline

• Advancing a platform of lipid signaling modulation drug candidates targeting pain, cancer, anxiety, depression, and other conditions.

• Pipeline includes ART27.13 (dual cannabinoid receptor agonist), ART26.12 (FABP5 inhibitor), and ART12.11 (CBD:TMP cocrystal), each at various clinical and preclinical stages.

• Multiple value-driving milestones expected in the next 12–18 months, including Phase 2 and Phase 1 studies.

ART27.13 program highlights

• Designed for cancer-related anorexia and cachexia, conditions affecting up to 80% of advanced cancer patients with no FDA-approved treatments.

• Demonstrated dose-dependent weight gain and increased activity in clinical studies, with a favorable safety profile up to 1300 μg daily.

• Phase 2 CARES trial interim results showed an average 6% weight increase at highest dose versus 5% decrease with placebo.

• Most common adverse events were mild, including somnolence and dry mouth; no serious or fatal events related to treatment.

ART26.12 program highlights

• FABP5 inhibitor targets chemotherapy-induced peripheral neuropathy (CIPN), a condition with no FDA-approved therapies affecting up to 40% of treated cancer patients.

• Preclinical studies showed significant reversal of neuropathic pain in animal models.

• Phase 1 study in healthy volunteers demonstrated excellent safety, predictable pharmacokinetics, and a wide therapeutic window.